Mizuho Securities Maintains a Buy Rating on Xeris Pharmaceuticals (XERS)
In a report issued on September 12, Difei Yang from Mizuho Securities maintained a Buy rating on Xeris Pharmaceuticals (XERS), with a price target of $14.00. The company’s shares closed last Monday at $5.12.
According to TipRanks.com, Yang is ranked 0 out of 5 stars with an average return of -9.7% and a 33.5% success rate. Yang covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Revance Therapeutics, and Nektar Therapeutics.
Currently, the analyst consensus on Xeris Pharmaceuticals is a Strong Buy with an average price target of $11.60.
See today’s analyst top recommended stocks >>
The company has a one-year high of $11.16 and a one-year low of $1.42. Currently, Xeris Pharmaceuticals has an average volume of 3.8M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol™ and XeriJect™ formulation technologies. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.
Read More on XERS: